Intravenous Iron Pre-treatment in Prognathic Surgery

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the present study is to determine the impact of preoperative IV-iron (ferric carboxy maltose) supplementation on postoperative hematocrit values and allogenic blood transfusion amount in patients undergoing elective prognathic surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Konkuk University Medical Center
• Treatments: Ferric Compounds

Criteria

Inclusion Criteria:

• Patients with prognathism in undergoing elective prognathic surgery

• Patients provided a written informed consent.

• Patients with s-ferritin < 300 mg/dl (male) or 200 mg/dl (female)

• Patients with preoperative Hematocrit > 39% (male) and > 36% 9female)serum hemoglobin >13 g/dL (male) and >12 g/dL (female)

Exclusion Criteria:

• Patients with history of anaphylaxis, iron overload, active infection.

• Patients with endocrine disease

• Patients received or receiving intraoperative and preoperative blood salvaged, allogenic blood transfusion, anti-fibrinolytic agents or recombinant human erythropoietin, or undergoing acute normovolemic hemodilution.